Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.35 0.74 (3.42%) Market Cap: 1.59 Bil Enterprise Value: 1.33 Bil PE Ratio: 203.18 PB Ratio: 3.66 GF Score: 62/100

Kiniksa Pharmaceuticals Ltd at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 12:30PM GMT
Release Date Price: $16.93 (+2.23%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Barclay's Global Healthcare Conference. My name's Geoff Meacham. I'm the Senior Biopharma Analyst here. And it's my pleasure to have Kiniksa Pharmaceuticals presenting this morning. Speaking on behalf of Kiniksa and on stage here, we have Sanj Patel, who is CEO; and John Paolini, who is the Chief Medical Officer.

Sanj?

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Thank you, Geoff. Good morning. It's good to be here. Thank you also to Barclays for hosting us today. We're excited to review our pipeline. As Geoff mentioned, John Paolini, our Chief Medical Officer, and I will review it in detail today. Incidentally, our mantra at Kiniksa is every second counts, so we're going to get right into it. Thank you.

Please note that we will be making forward-looking statements today that are subject to risks and uncertainties. A review of these risk factors and statements are on this slide as well as under the heading

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot